Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

K. Jabbour, Salma; Hyeong Lee, Ki; Frost, Nikolaj; В. Бредер, В.; M. Kowalski, Dariusz; Pollock, Theodore; Levchenko, E.; Reguart, Noemı́; Martínez‐Martí, Alex; Houghton, Baerin; Paoli, Jean-Baptiste; Safina, Sufia; Park, Keunchil; Komiya, Takefumi; Sanford, Amy; Boolell, Vishal; Liu, Hong; Samkari, Ayman; M. Keller, Steven; Reck, Martin

doi:10.1001/jamaoncol.2021.2301

Public

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

Published in JAMA Oncology • Jun 4, 2021

Authors:

Salma K. Jabbour

Ki Hyeong Lee

Nikolaj Frost

Abstract

IMPORTANCE: Administration of pembrolizumab plus concurrent chemoradiation therapy (cCRT) may provide treatment benefit to patients with locally advanced, stage III non-small cell lung cancer (NSCLC). OBJECTIVE: To evaluate treatment outcomes and safety of pembrolizumab plus cCRT in stage III NSCLC....

Subject

Medicine

Pembrolizumab

Carboplatin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!